Evidence map›Paper›PMID 41951614›Full record

ArticleNature communications2026

Skeletal editing via multi-step engineering of a modular polyketide synthase.

Kei Kudo, Takuya Hashimoto, Takayoshi Awakawa, Lihan Zhang, Takehiro Nishimura, Junko Hashimoto, Ikuko Kozone, Noritaka Kagaya, Hikaru Suenaga, Adrian T Keatinge-Clay and 2 more

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Kei Kudo *National Institute of Advanced Industrial Science and Technology (AIST), Tokyo, Japan.ORCID http://orcid.org/0000-0001-7500-9462
Takuya Hashimoto *National Institute of Advanced Industrial Science and Technology (AIST), Tokyo, Japan.ORCID http://orcid.org/0000-0002-6261-453X
Takayoshi Awakawa *Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan.ORCID http://orcid.org/0000-0003-2575-3175
Lihan Zhang *Department of Chemistry, School of Science and Research Center for Industries of the Future, Zhejiang Key Laboratory of Precise Synthesis of Functional Molecules, Westlake University, Hangzhou, China.ORCID http://orcid.org/0000-0003-4364-6242
Takehiro NishimuraTechnology Research Association for Next Generation Natural Products Chemistry, Tokyo, Japan.ORCID http://orcid.org/0000-0002-6600-9193
Junko HashimotoJapan Biological Informatics Consortium (JBIC), Tokyo, Japan.ORCID http://orcid.org/0000-0002-3831-1846
Ikuko KozoneJapan Biological Informatics Consortium (JBIC), Tokyo, Japan.
Noritaka KagayaTechnology Research Association for Next Generation Natural Products Chemistry, Tokyo, Japan.
Hikaru SuenagaNational Institute of Advanced Industrial Science and Technology (AIST), Tokyo, Japan.ORCID http://orcid.org/0000-0003-2218-9273
Adrian T Keatinge-ClayDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.ORCID http://orcid.org/0000-0002-4358-7628
Ikuro AbeGraduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan.ORCID http://orcid.org/0000-0002-3640-888X
Kazuo Shin-YaNational Institute of Advanced Industrial Science and Technology (AIST), Tokyo, Japan. k-shinya@aist.go.jp.ORCID http://orcid.org/0000-0002-4702-0661

Funding

Harnessing Polyketide Assembly Lines for Medicinal ChemistryR01GM145992 · NIGMS · UNIVERSITY OF TEXAS AT AUSTIN · PI KEATINGE-CLAY, ADRIAN TRISTAN · 2022 to 2025
$1.3M
Japan Agency for Medical Research and Development (AMED) JP19ae0101045MEXT | Japan Society for the Promotion of Science (JSPS) JP23H04569MEXT | Japan Society for the Promotion of Science (JSPS) JP23H05474NIGMS NIH HHS R01 GM145992U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS) GM145992
6 · The paper itself

Abstract

Assembly line biosynthesis creates numerous structurally diverse natural products using a common modular synthetic strategy. The collinearity between the architectures of modular polyketide synthases (PKS) and the structures of their polyketide products would seem to render these biosynthetic machineries excellent platforms for designer biosynthesis, yet reliable strategies to reprogram these assembly lines without diminishing their activities have not been identified. Here, as a best practice for PKS engineering, we demonstrate the reprogramming of the mediomycin PKS without significant loss of productivity. Using in vitro CRISPR/Cas9 gene editing followed by heterologous expression, we reconstruct an inaccessible drug lead of the fibrinogen receptor, tetrafibricin, at 82 ± 3 mg/L yield, retaining 26% productivity after five-step module editing using an evolution-supported cut site, downstream of the acyltransferase domain. A macrocyclic aminopolyol is also accessed through thioesterase swapping. These results pave the way toward the rational reprogramming of PKSs to access desired complex organic molecules.

Indexed as

Gene EditingPolyketide SynthasesProtein EngineeringAcyltransferasesBacterial ProteinsCRISPR-Cas SystemsMacrolidesStreptomycesAcyltransferasesBacterial ProteinsMacrolidesPolyketide Synthases

Identifiers

PMID41951614
PMCPMC13237034

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.